CREBBP and neoplasm: Suspicion that CREBBP may be a tumor suppressor first arose in the mid-1990s, when heterozygous germline mutations were identified in the setting of Rubinstein-Taybi syndrome, a developmental disorder with an increased prevalence of cancer, including leukemia and lymphoma (Petrij et al., 1995).